MorphoSys announces that Janssen receives approval for Tremfya® in Europe
MorphoSys (Munich, Germany) reveals that its licensee, Janssen, has received approval for Tremfya® from the European Commission. Tremfya® is a human anti-IL-23 monoclonal antibody that is utilized to treat moderate-to-severe plaque psoriasis. It was developed by Janssen and generated using MorphoSys’ HuCAL antibody library technology.
Simon Moroney, Chief Executive Officer of MorphoSys, commented: “We are very pleased that Janssen has now received market authorization for Tremfya® in Europe after U.S. approval was granted in July of this year. We expect this drug will provide an important treatment option for patients living with moderate-to-severe plaque psoriasis.”
Markus Enzelberger, Chief Scientific Officer of MorphoSys, concluded: “Guselkumab is the first antibody that has received approval in Europe based on MorphoSys’s technologies. With more than 100 MorphoSys compounds currently in development, we look forward to advancing novel antibodies in a wide variety of serious diseases where we see a strong need for alternative treatment options.”
